<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100827004641N19</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-27</date_registration>
      <primary_sponsor>Physical Medicine and Rehabilitation Research Center of Tabriz</primary_sponsor>
      <public_title>Comparıson between clınıcal effects of ıntra-artıcular ozone and intra-articular steroıd injection ın the treatment of chronic ankle osteoarthrıtıs</public_title>
      <acronym></acronym>
      <scientific_title>Comparıson between clınıcal effects of ıntra-artıcular ozone and intra-articular steroıd injection ın the treatment of chronic ankle osteoarthrıtıs</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59489</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation was performed using block randomization using software (RAS). The size of the blocks is 4, which includes an equal number of each intervention with a 1: 1 allocation ratio. Blocking is done by a person not involved in sampling and data analysis. To hide the allocation, the type of intervention was written on a piece of paper using the letters A and B and placed in matte and numbered envelopes. The envelopes were given to the participants in the order of the participants, Blinding description: It was not possible to blind patients due to the difference in the injection material, so the volunteers
were aware of what treatment method was used in each group. The injections were performed by a physical medicine specialist.
Data researchers, data analyzers, and outcome evaluators were blind. They were not aware of the intervention performed on each group of patients. Only the final data in the form of the first and second groups and random numbers assigned to each patient was available.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Chronic Osteoartritis of Ankle.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: corticosteroid injection: mixture of 40 mg of triamcinolone and 1 mg of lidocaine 2% was injected . Mortis join was the dite of injection. On the inter-maleular line, we entered the ankle joint space in 2 inches medial to the lateral maleus. With Needle 23 in the steroid therapy group before the start of the study, one month after the methylprednisolone injection and 6 months after the injection, the following items were recorded for each patient: Pain by the theoretical analog standard (VAS) 2) FADI Foot And Ankle Disability Index ). Intervention 2: Intervention group: ozone injection: 5 cc ozone with a concentration of 30 micrograms per ml with half a cc of 2% lidocaine was injected into the joint. Ozone injections were given to each patient once a week for 3 sessions. Mortis joint was  injection site. Patient was in the supine position and the ankle was  in the neutral position .in the sterile condition through the dorsal depression of the ankle on the intermalleular line in 2 inches medial to the lateral maleus entered the joint space. With Needle 23 in the ozone therapy group before the start of the study, at the end of the third session, one month later and 6 months after the end of the ozone therapy sessions, the following items are recorded for each patient: Pain by Theoretical Analogue Criterion (VAS) 2) FADI) Foot And Ankle Disability Index).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Decision will be made based on the result of the research.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bina Eftekharsadat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physical Medicine and Rehabilitation Research Center of Tabriz, imam reza hospital, Golgasht st.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 1336 4672</telephone>
        <email>binasadat@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Bina Eftekhar Sadat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physical Medicine and Rehabilitation Center, Imam reza hospital, The Golgasht street, Azadi avenue</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 1385 7765</telephone>
        <email>binasadat@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Existence of symptoms of ankle osteoarthritis for at least 3 months
Minimum score of 3 in the criterion (VAS)
Absence of inflammatory rheumatic diseases
Failure to respond to conservative drug and physiotherapy treatments during the past 6 months
Satisfaction of patients participating in the study
rug and physiotherapy treatments during the past 6 months
Aged 45 years and older</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Severe osteoarthritis (Grade 4 candidates for joint replacement surgery)
Rumatic disease
Clearly visible deformity of the ankle
Ankylosis
Ozone contraindications include: -Hyperthyroidism -Thrombocytopenia -Pregnancy Recent history of heart attack G-6PD deficiency
Definitive and relative contraindications to steroid injections include: Bacteremia, sepsis, intra-articular or pre-uricular infection, history of post-injection allergies Specific skin lesion at the injection site</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M19.079</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primary osteoarthritis, unspecified ankle and foot</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: corticosteroid injection: mixture of 40 mg of triamcinolone and 1 mg of lidocaine 2% was injected . Mortis join was the dite of injection. On the inter-maleular line, we entered the ankle joint space in 2 inches medial to the lateral maleus. With Needle 23 in the steroid therapy group before the start of the study, one month after the methylprednisolone injection and 6 months after the injection, the following items were recorded for each patient: Pain by the theoretical analog standard (VAS) 2) FADI Foot And Ankle Disability Index )</i_keyword>
      <i_keyword>Intervention group: ozone injection: 5 cc ozone with a concentration of 30 micrograms per ml with half a cc of 2% lidocaine was injected into the joint. Ozone injections were given to each patient once a week for 3 sessions. Mortis joint was  injection site. Patient was in the supine position and the ankle was  in the neutral position .in the sterile condition through the dorsal depression of the ankle on the intermalleular line in 2 inches medial to the lateral maleus entered the joint space. With Needle 23 in the ozone therapy group before the start of the study, at the end of the third session, one month later and 6 months after the end of the ozone therapy sessions, the following items are recorded for each patient: Pain by Theoretical Analogue Criterion (VAS) 2) FADI) Foot And Ankle Disability Index)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount af Reduce in pain after injection. Timepoint: 1 month after injection and 6 months after injection. Method of measurement: FADI questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Improvement of function and reduce in pain of ankle. Timepoint: Before,1 month an 6 months after injection. Method of measurement: FADI questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Physical Medicine and Rehabilitation Research Center of Tabriz</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-12</approval_date>
        <contact_name>Ethic committee of Tabriz university of medical sciences</contact_name>
        <contact_address>Golgasht Avenue Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
